Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

G. Rivera; W. P. Bowman; A. T. Look; W. E. Evans; D. Kalwinsky; G. V. Dahl

doi:10.1016/S0305-7372(82)80078-9

Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

G. Rivera, W. P. Bowman, A. T. Look, W. E. Evans, D. Kalwinsky, G. V. Dahl

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

Original language	English
Pages (from-to)	53-57
Number of pages	5
Journal	Cancer Treatment Reviews
Volume	9
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/S0305-7372(82)80078-9
State	Published - Jun 1982

Access to Document

10.1016/S0305-7372(82)80078-9

Cite this

@article{c7481d0bbed548e3b3260824c5f1b361,

title = "Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood",

abstract = "In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.",

author = "G. Rivera and Bowman, {W. P.} and Look, {A. T.} and Evans, {W. E.} and D. Kalwinsky and Dahl, {G. V.}",

year = "1982",

month = jun,

doi = "10.1016/S0305-7372(82)80078-9",

language = "English",

volume = "9",

pages = "53--57",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

AU - Rivera, G.

AU - Bowman, W. P.

AU - Look, A. T.

AU - Evans, W. E.

AU - Kalwinsky, D.

AU - Dahl, G. V.

PY - 1982/6

Y1 - 1982/6

N2 - In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

AB - In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

UR - http://www.scopus.com/inward/record.url?scp=0020427484&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(82)80078-9

DO - 10.1016/S0305-7372(82)80078-9

M3 - Article

C2 - 6181873

AN - SCOPUS:0020427484

SN - 0305-7372

VL - 9

SP - 53

EP - 57

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - SUPPL. 1

ER -

Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

Abstract

Access to Document

Other files and links

Fingerprint

Cite this